Elicio Therapeutics Inc. Total Liabilities

Latest as of June 2026: $23.39 Million USD

Elicio Therapeutics Inc. total liabilities. Based on the latest financial reports, Elicio Therapeutics Inc. (ELTX) has total liabilities worth $23.39 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ELTX asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Elicio Therapeutics Inc. (2012–2025)

Total liabilities of Elicio Therapeutics Inc. from 2012 to 2025. This chart illustrates how Elicio Therapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data.

Elicio Therapeutics Inc. Competitors by Total Liabilities

The table below lists competitors of Elicio Therapeutics Inc. ranked by their total liabilities.

Company	Country	Total Liabilities
Chorokbaem Media Co. Ltd KQ:047820	Korea	₩79.12 Billion
Vinyl Group Ltd AU:VNL	Australia	AU$5.15 Million
Altustfi WAR:ALI	Poland	zł20.07 Million
CVC Technologies TWO:4744	Taiwan	NT$841.42 Million
Farm Pride Foods Ltd AU:FRM	Australia	AU$47.50 Million
MACH7 Technologies Ltd AU:M7T	Australia	AU$18.63 Million
Metal Sky Star Acquisition Corporation Ordinary shares NASDAQ:MSSA	USA	$8.21 Million
Indo Thai Securities Limited NSE:INDOTHAI	India	Rs657.61 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Elicio Therapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Elicio Therapeutics Inc. (ELTX) total assets.

Liquidity & Leverage Metrics

Elicio Therapeutics Inc. Total Liabilities Ratios Explained

Elicio Therapeutics Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric	Value	Description
Current Ratio	2.77	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.95	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.75	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Elicio Therapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Elicio Therapeutics Inc. (2012–2025)

The table below shows the annual total liabilities of Elicio Therapeutics Inc. from 2012 to 2025.

Year	Total Liabilities	Change
2025-12-31	$24.23 Million	-38.65%
2024-12-31	$39.49 Million	+150.36%
2023-12-31	$15.77 Million	+14.72%
2022-12-31	$13.75 Million	-8.38%
2021-12-31	$15.01 Million	-89.11%
2020-12-31	$137.80 Million	+352.21%
2019-12-31	$30.47 Million	+294.87%
2018-12-31	$7.72 Million	+16.87%
2013-12-31	$6.60 Million	-2.78%
2012-12-31	$6.79 Million	--

About Elicio Therapeutics Inc.

NASDAQ:ELTX USA Biotechnology

Market Cap

$43.23 Million

Market Cap Rank

#22199 Global

#4925 in USA

Share Price

$1.65

Change (1 day)

+8.94%

52-Week Range

$1.40 - $14.85

All Time High

$257.40